HAE
Haemonetics Corporation
HAE has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over HAE overall, supported by stronger fundamentals and stronger modeled upside.
HAE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Under pressure |
HAE's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
HAE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 25x | $56.99 | -54% |
| Fair | 41x | $93.28 | -24% |
| Current | 54x | $123 | — |
| Expensive | 66x | $150 | +22% |
Historical ranges are pointers, not guarantees.
HAE's PE is in its expensive range at 54x.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over HAE in the historical PE scenario, which offers more potential upside but is not a forecast.
HAE Forward outlook
There aren't enough analyst estimates for HAE to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
HAE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $2.26 | -34% |
| Q2 2026 | $2.07 | -37% |
| Q1 2026 | $2.05 | -38% |
| Q4 2025 | $3.63 | +43% |
| Q3 2025 | $3.42 | +42% |
| Q2 2025 | $3.27 | +47% |
| Q1 2025 | $3.31 | +45% |
| Q4 2024 | $2.54 | +2.8% |
HAE has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
HAE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $357.8M | +9.3% |
| Q2 2026 | $339.4M | +5.6% |
| Q1 2026 | $346.4M | +4.8% |
| Q4 2025 | $339M | -2.7% |
| Q3 2025 | $327.3M | -5.3% |
| Q2 2025 | $321.4M | -4.4% |
| Q1 2025 | $330.6M | -3.7% |
| Q4 2024 | $348.5M | +3.7% |
HAE's revenue has picked up after two years of holding roughly level: $358M last quarter, up 9.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +3.1 points |
| Q2 2026 | 17% | +0.2 points |
| Q1 2026 | -6.7% | -28 points |
| Q4 2025 | 20% | +2.9 points |
| Q3 2025 | 18% | +2.9 points |
| Q2 2025 | 17% | +4.9 points |
| Q1 2025 | 22% | +13 points |
| Q4 2024 | 17% | +3.3 points |
HAE has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over HAE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
HAE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $113.3M | +6.6% |
| Q2 2026 | $44.4M | +226% |
| Q1 2026 | $53.3M | -47% |
| Q4 2025 | $87.2M | +148% |
| Q3 2025 | $106.3M | +170% |
| Q2 2025 | $13.6M | +$46.7M |
| Q1 2025 | $100.9M | +86% |
| Q4 2024 | $35.2M | +$58.1M |
HAE has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
HAE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +759K shares |
| 1 year | -2.5% | -1.2M shares |
| 3 years | -9.6% | -4.9M shares |
| 5 years | -9.7% | -5M shares |
| Available history | -10% | -5.2M shares |
HAE has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q1 2025 | $150M |
| Q4 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HAE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 2.4x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 2.7x | Moderate |
| Q4 2024 | 3.1x | Elevated |
HAE's net debt is about 3.0 years of its operating earnings (EBITDA), up from 2.6 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over HAE on leverage, with a lower net debt burden relative to earnings.
HAE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 78.5 | Overbought |
| Stochastic | 82.3 | Overbought |
HAE's weekly RSI is 79 (overbought) and its Stochastic is 82 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
HAE PE vs Healthcare Sector
| Metric | HAE | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 26x | 110% above |
| PE % | 67 | 29 | 38 pts above |
HAE is trading at 54x earnings, a 110% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over HAE on valuation relative to its sector.
HAE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $116.0 | 5.8% above |
| 20 week MA | $101.3 | 21% above |
| 50 week MA | $80.9 | 52% above |
| 100 week MA | $72.9 | 68% above |
| 200 week MA | $78.4 | 57% above |
HAE has climbed back above all five of its weekly moving averages, and it's now 57% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
HAE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $115.9 | $118.8 | +2.4% |
| 2021 | $118.8 | $54.2 | -54% |
| 2022 | $54.2 | $79.2 | +46% |
| 2023 | $79.2 | $85.5 | +8% |
| 2024 | $85.5 | $77.6 | -9.3% |
| 2025 | $77.6 | $80.3 | +3.5% |
| 2026 YTD | $80.3 | $122.7 | +53% |
HAE has finished higher in four of the last six years. It's up 53% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over HAE on returns for 2026, with the stronger performance.